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Introduction
Results
Of the 126 samples, 92 were identified as C. albicans, 24 as C. glabrata, 4 as C. tropicalis, 3 as C. krusei, 2 as C.
parapsilopsis/lusitaneae/kefyr, and 1 as C. dubliniensis.
The results from Table 1 demonstrate that C. albicans, C. tropicalis and C. krusei strains showed no resistance to echinocandin drugs,
while C. glabrata strains showed high resistance levels against micafungin.
In the case of the azole drugs, the reverse was seen: C. albicans strains were more resistant to azoles (greater than or equal to 50%
resistance in all azoles for C. albicans), with C. glabrata responding better to this class of drugs. The C. dubliniensis strain and two
species identified as C. parapsilopsis/lusitaneae/kefyr showed no resistance to azole drugs, with C. tropicalis strains showing
susceptibility to both fluconazole and voriconazole.
Posaconazole results were not included in this study, as there are no breakpoints for this drug. However, this antifungal showed very
similar results to voriconazole. 5-flucytosine showed very promising results against most species tested. The exceptions were C. krusei,
with only one isolate (33.3% of total) showing intermediate resistance, and C. albicans, where 5.4% of isolates were totally resistant.
All Candida species contained isolates that were completely resistant to amphotericin B.
Discussion
Materials and Methods
Oral Candida samples were collected from 126 HIV-positive patients presenting with white pseudomembranous plaque in the tongue or
visible oral candidiasis at the Regional Hospital in Bamenda, Cameroon, by scraping the patient’s oral mucosa and tongue using a sterile
mouth swab. Ethical clearance for this project was granted by the Ethics Committee of the University of the Western Cape.
The samples were transported to a private laboratory in Bamenda for microscopic examination and inoculation onto Candida selective
media. The samples were then sent to the Medical Microbiology laboratories at the University of the Western Cape, South Africa, for
species confirmation.
Running of the samples on the TREK Sensititre system was done by diluting second-generation Candida strains onto sterile phosphate
buffered saline tubes to a 0.5 McFarland standard, using the supplied TREK nephelometer. This was followed by vortexing the
suspension according to protocol, dispensing 100µl of the solution into the YeastOne broth, dispensing the inoculated broth onto the
YO9 plate using an Ovation 25-1250µl multichannel pipette (VistaLab, NY, USA, cat. no. 1160-1250) and incubating for 24 hours at
37°C. The plates were then read using the Vizion plate reader and the TREK SWIN software.
Type strains of C. albicans (ATCC 90028 and NCPF 3281), C. krusei (ATCC 2159), C. glabrata (ATCC 26512), C. tropicalis (ATCC
950) and C. dubliniensis (NCPF 3949a) served as positive controls for the species differentiation and drug susceptibility testing.
Newly developed species-specific clinical breakpoints were used for the determination of echinocandin drug resistance (anidulafungin,
caspofungin and micafungin) for C. albicans, C. tropicalis and C. krusei (Pfaller et al, 2012), while CLSI breakpoint categories were
used for 5-flucytosine, itraconazole, fluconazole and amphotericin B (Eraso et al, 2008) and proposed breakpoints were used for
voriconazole (Pfaller et al, 2006). Statistical analysis was done by means of Chi-square tests using SPSS.
Background: Candida infections are a common cause of death in
immunocompromised patients. The prevalence and anti-mycotic
drug susceptibility profiles of Candida species from Cameroon in
Africa are unavailable. This study was prompted by an increasing
incidence of treatment failure. Drug susceptibility profiles,
necessary to improve treatment outcomes, is particularly
important in countries where the sale of antimicrobials and
antifungals is uncontrolled and resistance may emerge due to the
indiscriminate use.
Objective: The goal of this study was to characterize and
determine drug susceptibility of oral Candida species in
Cameroonian patients with HIV/AIDS.
Materials and Methods: Candida species were isolated from the
oral cavity of 126 HIV-positive patients attending a local
HIV/AIDS clinic in the Cameroon. Drug susceptibility to azoles
and echinocandins was determined using the commercial TREK
Sensititre® YeastOne™ platform that provides the minimal
inhibitory concentration of amphotericin B, 5-flucytosine,
anidulafungin, caspofungin, micafungin, fluconazole,
itraconazole, posaconazole, and voriconazole.
Results: Ninety two isolates identified were Candida albicans.
Remaining isolates were C. glabrata (24), C. tropicalis (4), C.
krusei (3), C. parapsilopsis/lusitanreae/keyfr (2), and one isolate
was C. dubliniensis. More than 50% of C. albicans isolated were
resistant to azoles but 115 Candida species (87%) were
susceptible to amphotericin B. Twenty one of the twenty four
C.glabrata identified (88%) were resistant to micafungin. The
majority of Cameroonian Candida species were sensitive to
flucytosine (5-FC) (95%) and echinocandins (79%).
Conclusions: The report of azole resistance in all Candida
species isolated from immunocompromised patients in Cameroon
is a new and important observation. We found the approach using
a broad screening platform an effective means to obtain data
rapidly. We propose confirmation of these data and regional
surveillance of Candida species in other areas in Cameroon and
surrounding countries to develop an effective public health
management and treatment strategy.
HIV-infected individuals are prone to Candida species
infections, which can result in increased patient morbidity and
mortality due to oropharyngeal or systemic dissemination. The
need for antifungal drug susceptibility in the African continent
is imperative, due to high infection rates, the lack of
surveillance studies and the uncontrolled distribution of
medications, which can result in increased drug resistance. This
is especially true in resource-poor countries, where very few
related studies have been done.
The TREK Sensititre YeastOne 9 (YO9) system is a broth
microdilution method that provides multiple antifungal drug
susceptibility testing. This methodology has the advantage of
being standardized to the Clinical and Laboratory Standards
Institute (CLSI) standards (Eraso et al, 2008, Pfaller et al,
2012). The technology consists of microtiter plates embedded
with nine different drugs (anidulafungin, micafungin,
caspofungin, 5-flucytosine, posaconazole, voriconazole,
itraconazole, fluconazole and amphotericin B) in ascending
concentrations. The wells are also coated with a colorimetric
agent, allowing for the minimum inhibitory concentration
(MIC) of each drug to be easily detected both with the naked
eye and with the supplied Vizion computer-assisted plate
reading system.
The objective of this study was to investigate the drug
susceptibility profiles of different Candida species isolated from
HIV-infected Cameroonian patients using the TREK Sensititre
system.
The need for a simple antifungal drug susceptibility platform for use in clinical laboratories is imperative, as the
emergence of resistant Candida species is a cause of concern. The use of the TREK Sensititre platform for drug
susceptibility testing can be done rapidly and with minimal training and reagents and is therefore a promising method for
use in resource-limited laboratories in Africa.
This study points out that fluconazole, the most widely available medication for C. albicans infections in the African
continent, is only working on half of the patients or less. The same occurs in the case of the other azole drugs tested. It is
suggested that the dispensing of these antibiotics should not be arbitrary, as this procedure promotes antibiotic resistance.
Dispensing should be based upon known antibiotic susceptibility profiles of the Candida species present in the local
population.
We emphasize that there is a need for regional surveillance of Candida species, as this study has shown that certain
species, such as the prevalent C. albicans do not respond to specific antifungal drugs that might be dispensed empirically.
Table 1: Overall drug susceptibility results according to Candida species ( - : no breakpoint available for the
organism/drug). The different Candida species identified in the study are seen in the x-axis, with the different
drugs on the YO9 plate and respective susceptibility breakpoints shown in the y-axis.
Fig.1.: Drug panel and different results seen on the TREK Sensititre plates.
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b: Susceptible strain (growth only in red circled wells)
c: Azole drug resistance
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